期刊
MOVEMENT DISORDERS
卷 27, 期 12, 页码 1484-1492出版社
WILEY
DOI: 10.1002/mds.25173
关键词
PET; fMRI; cognition; executive functions; PD
资金
- Canadian Institutes of Health Research [MOP 110962]
- Canada Research Chair program
- E.J. Safra Foundation
- Parkinson Society Canada
Patients with Parkinson's disease (PD) often develop a spectrum of cognitive symptoms that can evolve into dementia. Dopamine (DA) replacement medications, though improving motor symptoms, can exert both positive and negative effects on cognitive ability, depending on the severity of the disease and the specific skill being tested. By considering the behavioral and clinical aspects of disease- and treatment-mediated changes in cognition alongside the pathophysiology of PD, an understanding of the factors that govern the heterogeneous expression of cognitive impairment in PD is beginning to emerge. Here, we review the neuroimaging studies revealing the neural correlates of cognitive changes after DA loss and DA replacement as well as those that may accompany the conversion from milder stages of cognitive impairment to frank dementia. (c) 2012 Movement Disorder Society
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据